31. Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company is currently preparing the calculation for basic and diluted earnings per share and the related disclosures for Fitzgerald's financial statements. Attached is selected financial information for the fiscal year June 30, 2022. The following transactions have also occurred at Fitzgerald. 1. Options were granted on July 1,2021 to purchase 200,000 shares at $15 per share. Although no options were exercised during fiscal year 2022, the average price per common share during fiscal year 2022 was $20 per share. 2. Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2016. 3. The preferred stock was issued in 2021. 4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2022. 5. The 1,000,000 shares of common stock were outstanding for the entire 2022 fiscal year. 6. Net income for fiscal year 2022 was $1,500,00 and the average income tax rate is 40%. Instructions: For the fiscal year ended June 30, 2022, calculate the following for Fitzgerald Pharmace A) Basic Earnings Per Share B) Diluted Earnings Per Share